e10vq
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
Form 10-Q
(Mark One)
|
|
þ
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 29, 2009
OR
|
|
o |
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
For the transition period
from
to .
Commission file number 1-5353
TELEFLEX INCORPORATED
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
|
|
23-1147939
|
(State or other jurisdiction
of
incorporation or organization)
|
|
(I.R.S. employer identification
no.)
|
|
|
|
155 South Limerick Road,
Limerick, Pennsylvania
|
|
19468
|
(Address of principal executive
offices)
|
|
(Zip Code)
|
(610) 948-5100
(Registrants telephone
number, including area code)
(None)
(Former Name, Former Address and
Former Fiscal Year, If Changed Since Last Report)
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated
filer þ
|
|
Accelerated
filer o
|
|
Non-accelerated
filer o
|
|
Smaller reporting
company o
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Act).
Yes o No þ
On April 17, 2009, 39,748,928 shares of the
registrants common stock, $1.00 par value, were
outstanding.
TELEFLEX
INCORPORATED
QUARTERLY REPORT ON
FORM 10-Q
FOR THE QUARTER ENDED MARCH 29, 2009
TABLE OF
CONTENTS
1
PART I
FINANCIAL INFORMATION
|
|
Item 1.
|
Financial
Statements
|
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars and shares in thousands, except per share)
|
|
|
Net revenues
|
|
$
|
469,675
|
|
|
$
|
542,110
|
|
Materials, labor and other product costs
|
|
|
273,551
|
|
|
|
328,671
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
196,124
|
|
|
|
213,439
|
|
Selling, engineering and administrative expenses
|
|
|
128,764
|
|
|
|
147,573
|
|
Net loss on sales of businesses and assets
|
|
|
2,597
|
|
|
|
18
|
|
Restructuring and other impairment charges
|
|
|
2,463
|
|
|
|
8,856
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest and taxes
|
|
|
62,300
|
|
|
|
56,992
|
|
Interest expense
|
|
|
25,402
|
|
|
|
31,083
|
|
Interest income
|
|
|
(214
|
)
|
|
|
(961
|
)
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before taxes
|
|
|
37,112
|
|
|
|
26,870
|
|
Taxes on income from continuing operations
|
|
|
10,462
|
|
|
|
11,662
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
|
26,650
|
|
|
|
15,208
|
|
|
|
|
|
|
|
|
|
|
Operating income from discontinued operations (including gain on
disposal of $275,787 and $0, respectively)
|
|
|
297,975
|
|
|
|
15,195
|
|
Taxes on income from discontinued operations
|
|
|
99,018
|
|
|
|
406
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
198,957
|
|
|
|
14,789
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
225,607
|
|
|
|
29,997
|
|
Less: Net income attributable to noncontrolling interest
|
|
|
236
|
|
|
|
187
|
|
Income from discontinued
operations attributable to noncontrolling interest
|
|
|
9,860
|
|
|
|
6,867
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to common shareholders
|
|
$
|
215,511
|
|
|
$
|
22,943
|
|
|
|
|
|
|
|
|
|
|
Earnings per share available to common shareholders:
|
|
|
|
|
|
|
|
|
Basic:
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.67
|
|
|
$
|
0.38
|
|
Income from discontinued operations
|
|
$
|
4.76
|
|
|
$
|
0.20
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5.43
|
|
|
$
|
0.58
|
|
|
|
|
|
|
|
|
|
|
Diluted:
|
|
|
|
|
|
|
|
|
Income from continuing operations
|
|
$
|
0.66
|
|
|
$
|
0.38
|
|
Income from discontinued operations
|
|
$
|
4.74
|
|
|
$
|
0.20
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
5.40
|
|
|
$
|
0.58
|
|
|
|
|
|
|
|
|
|
|
Dividends per share
|
|
$
|
0.340
|
|
|
$
|
0.320
|
|
Weighted average common shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
|
|
|
39,692
|
|
|
|
39,454
|
|
Diluted
|
|
|
39,876
|
|
|
|
39,709
|
|
Amounts attributable to common shareholders:
|
|
|
|
|
|
|
|
|
Income from continuing operations, net of tax
|
|
$
|
26,414
|
|
|
$
|
15,021
|
|
Discontinued operations, net of tax
|
|
|
189,097
|
|
|
|
7,922
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
215,511
|
|
|
$
|
22,943
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
2
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
ASSETS
|
Current assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
143,051
|
|
|
$
|
107,275
|
|
Accounts receivable, net
|
|
|
288,971
|
|
|
|
311,908
|
|
Inventories, net
|
|
|
406,829
|
|
|
|
424,653
|
|
Prepaid expenses and other current assets
|
|
|
19,658
|
|
|
|
21,373
|
|
Income taxes receivable
|
|
|
11,004
|
|
|
|
17,958
|
|
Deferred tax assets
|
|
|
64,407
|
|
|
|
66,009
|
|
Assets held for sale
|
|
|
7,773
|
|
|
|
8,210
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
941,693
|
|
|
|
957,386
|
|
Property, plant and equipment, net
|
|
|
332,407
|
|
|
|
374,292
|
|
Goodwill
|
|
|
1,447,005
|
|
|
|
1,474,123
|
|
Intangibles and other assets
|
|
|
1,062,419
|
|
|
|
1,090,852
|
|
Investments in affiliates
|
|
|
15,886
|
|
|
|
28,105
|
|
Deferred tax assets
|
|
|
6,864
|
|
|
|
1,986
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
3,806,274
|
|
|
$
|
3,926,744
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND SHAREHOLDERS EQUITY
|
Current liabilities
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
5,973
|
|
|
$
|
108,853
|
|
Accounts payable
|
|
|
109,710
|
|
|
|
139,677
|
|
Accrued expenses
|
|
|
111,724
|
|
|
|
125,183
|
|
Payroll and benefit-related liabilities
|
|
|
65,039
|
|
|
|
83,129
|
|
Derivative liabilities
|
|
|
22,972
|
|
|
|
27,370
|
|
Accrued interest
|
|
|
21,167
|
|
|
|
26,888
|
|
Income taxes payable
|
|
|
89,273
|
|
|
|
12,613
|
|
Deferred tax liabilities
|
|
|
4,786
|
|
|
|
2,227
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
430,644
|
|
|
|
525,940
|
|
Long-term borrowings
|
|
|
1,299,662
|
|
|
|
1,437,538
|
|
Deferred tax liabilities
|
|
|
324,942
|
|
|
|
324,678
|
|
Pension and postretirement benefit liabilities
|
|
|
170,016
|
|
|
|
169,841
|
|
Other liabilities
|
|
|
175,570
|
|
|
|
182,864
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
2,400,834
|
|
|
|
2,640,861
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Total common shareholders equity
|
|
|
1,401,329
|
|
|
|
1,246,455
|
|
Noncontrolling interest
|
|
|
4,111
|
|
|
|
39,428
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
1,405,440
|
|
|
|
1,285,883
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and equity
|
|
$
|
3,806,274
|
|
|
$
|
3,926,744
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
3
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Cash Flows from Operating Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
225,607
|
|
|
$
|
29,997
|
|
Adjustments to reconcile net income to net cash used in
operating activities:
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
(198,957
|
)
|
|
|
(14,789
|
)
|
Depreciation expense
|
|
|
14,509
|
|
|
|
16,266
|
|
Amortization expense of intangible assets
|
|
|
11,133
|
|
|
|
11,716
|
|
Amortization expense of deferred financing costs
|
|
|
2,641
|
|
|
|
1,468
|
|
Stock-based compensation
|
|
|
2,250
|
|
|
|
1,797
|
|
Net loss on sales of businesses and assets
|
|
|
2,597
|
|
|
|
18
|
|
Other
|
|
|
760
|
|
|
|
2,206
|
|
Changes in operating assets and liabilities, net of effects of
acquisitions:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(13,318
|
)
|
|
|
(29,155
|
)
|
Inventories
|
|
|
(11,903
|
)
|
|
|
15,999
|
|
Prepaid expenses and other current assets
|
|
|
1,681
|
|
|
|
669
|
|
Accounts payable and accrued expenses
|
|
|
(36,094
|
)
|
|
|
1,395
|
|
Income taxes payable and deferred income taxes
|
|
|
(5,360
|
)
|
|
|
(57,837
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities from continuing operations
|
|
|
(4,454
|
)
|
|
|
(20,250
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Proceeds from long-term borrowings
|
|
|
10,000
|
|
|
|
|
|
Reduction in long-term borrowings
|
|
|
(249,178
|
)
|
|
|
(13,421
|
)
|
Increase in notes payable and current borrowings
|
|
|
(659
|
)
|
|
|
10,159
|
|
Proceeds from stock compensation plans
|
|
|
367
|
|
|
|
1,602
|
|
Payments to noncontrolling interest shareholders
|
|
|
(295
|
)
|
|
|
(442
|
)
|
Dividends
|
|
|
(13,511
|
)
|
|
|
(12,622
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities from continuing operations
|
|
|
(253,276
|
)
|
|
|
(14,724
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities of Continuing Operations:
|
|
|
|
|
|
|
|
|
Expenditures for property, plant and equipment
|
|
|
(7,020
|
)
|
|
|
(7,468
|
)
|
Proceeds from sales of businesses and assets, net of cash sold
|
|
|
296,883
|
|
|
|
|
|
Payments for businesses and intangibles acquired, net of cash
acquired
|
|
|
(1,108
|
)
|
|
|
(350
|
)
|
Investments in affiliates
|
|
|
|
|
|
|
(100
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) investing activities from
continuing operations
|
|
|
288,755
|
|
|
|
(7,918
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Discontinued Operations:
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
17,183
|
|
|
|
14,283
|
|
Net cash used in financing activities
|
|
|
(11,075
|
)
|
|
|
(12,250
|
)
|
Net cash used in investing activities
|
|
|
(1,103
|
)
|
|
|
(291
|
)
|
|
|
|
|
|
|
|
|
|
Net cash provided by discontinued operations
|
|
|
5,005
|
|
|
|
1,742
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(254
|
)
|
|
|
(6,085
|
)
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
35,776
|
|
|
|
(47,235
|
)
|
Cash and cash equivalents at the beginning of the period
|
|
|
107,275
|
|
|
|
201,342
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of the period
|
|
$
|
143,051
|
|
|
$
|
154,107
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of the condensed
consolidated financial statements.
4
TELEFLEX
INCORPORATED AND SUBSIDIARIES
(Unaudited)
|
|
Note 1
|
Basis of
presentation
|
Teleflex Incorporated (referred to herein as we,
us, our, Teleflex and the
Company) is a diversified company specializing in
the design, manufacture and distribution of quality engineered
products and services. The Company serves a wide range of
customers in segments of the medical, aerospace and commercial
industries. The Companys products include: medical devices
used in critical care and anesthesia applications, surgical
instruments and devices, cardiac assist devices for hospitals
and healthcare providers and instruments and devices delivered
to medical device manufacturers; cargo-handling systems and
equipment used in commercial aircraft; and marine driver
controls, engine assemblies and drive parts, power and fuel
management systems and rigging products and services for
commercial industries.
The accompanying condensed consolidated financial statements of
the Company have been prepared in accordance with accounting
principles generally accepted in the United States of America
(US GAAP) for interim financial information and in
accordance with the instructions for
Form 10-Q
and
Rule 10-01
of
Regulation S-X.
Accordingly, they do not include all information and footnotes
required by US GAAP for complete financial statements.
The accompanying financial information is unaudited; however, in
the opinion of the Companys management, all adjustments
(consisting of normal recurring adjustments and accruals)
necessary for a fair statement of the financial position,
results of operations and cash flows for the periods reported
have been included. The results of operations for the periods
reported are not necessarily indicative of those that may be
expected for a full year.
This quarterly report should be read in conjunction with the
consolidated financial statements and notes thereto included in
the Companys audited consolidated financial statements for
the fiscal year ended December 31, 2008.
Certain reclassifications have been made to the prior year
condensed consolidated financial statements to conform to
current period presentation. Certain financial information is
presented on a rounded basis, which may cause minor differences.
|
|
Note 2
|
New
accounting standards
|
Fair Value Measurements: In September 2006,
the Financial Accounting Standards Board (FASB)
issued Statement of Financial Accounting Standards
(SFAS) No. 157, Fair Value
Measurements. SFAS No. 157 establishes a common
definition of fair value to be applied to US GAAP that requires
the use of fair value, establishes a framework for measuring
fair value, and expands disclosure about such fair value
measurements. Except as noted below, SFAS No. 157
became effective for fiscal years beginning after
November 15, 2007.
In February 2008, the FASB issued FASB Staff Position
(FSP)
157-2,
Partial Deferral of the Effective Date of Statement
157.
FSP 157-2
delays the effective date of SFAS No. 157 to fiscal
years beginning after November 15, 2008 for all
nonfinancial assets and nonfinancial liabilities, except those
that are recognized or disclosed at fair value in the financial
statements on a recurring basis (at least annually). The Company
adopted SFAS No. 157 as of January 1, 2008 with
respect to financial assets and financial liabilities. The
Company has adopted the provisions of
FSP 157-2
as of January 1, 2009. SFAS No. 157 and the
related
FSP 157-2
did not have a material impact on the Companys results of
operations, cash flows or financial position upon adoption.
Refer to Note 11 for additional discussion on fair value
measurements.
Business Combinations: In December 2007, the
FASB issued SFAS No. 141(R), Business
Combinations. SFAS No. 141(R) replaces
SFAS No. 141, Business Combinations.
SFAS No. 141(R) retains the fundamental requirements
in SFAS No. 141 that the acquisition method of
accounting (which SFAS No. 141 called the purchase
method) be used for all business combinations and for an
acquirer to be identified for each business combination.
SFAS No. 141(R) defines the acquirer as the entity
that obtains control of one or more businesses in the business
combination and establishes the acquisition date as the date
that the acquirer achieves control.
SFAS No. 141(R)s
5
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
scope is broader than that of SFAS No. 141, which
applied only to business combinations in which control was
obtained by transferring consideration.
SFAS No. 141(R) replaces SFAS No. 141s
cost-allocation process and requires an acquirer to recognize
the assets acquired, the liabilities assumed, and any
noncontrolling interest in the acquiree at the acquisition date,
measured at their fair values as of that date, with limited
exceptions. In addition, SFAS No. 141(R) changes the
allocation and treatment of acquisition-related costs,
restructuring costs that the acquirer expected but was not
obligated to incur, the recognition of assets and liabilities
assumed arising from contingencies and the recognition and
measurement of goodwill. This statement is effective for fiscal
years beginning after December 15, 2008 and is to be
applied prospectively to business combinations.
On April 1, 2009, the FASB issued FSP 141(R)-1,
Accounting for Assets Acquired and Liabilities Assumed in
a Business Combination That Arise from Contingencies.
FSP 141(R)-1 amends and clarifies issues that arose
regarding initial recognition and measurement, subsequent
measurement and accounting and disclosure of assets and
liabilities arising from contingencies in a business
combination. FSP 141(R)-1 is effective for fiscal years
beginning after December 15, 2008.
SFAS No. 141(R) and the related FSP 141(R)-1 did
not have an impact on the Companys results of operations,
cash flows or financial position upon adoption; however, future
transactions entered into by the Company will need to be
evaluated under the requirements of these standards.
Noncontrolling Interests: In December 2007,
the FASB issued SFAS No. 160, Noncontrolling
Interests in Consolidated Financial Statements an
amendment of ARB No. 51. SFAS No. 160
amends Accounting Research Bulletin (ARB) 51 to
establish accounting and reporting standards for the
noncontrolling interest in a subsidiary, sometimes referred to
as minority interest, and for the deconsolidation of a
subsidiary. It clarifies that a noncontrolling interest in a
subsidiary is an ownership interest in the consolidated entity
that should be reported as equity in the consolidated financial
statements. SFAS No. 160 requires that a
noncontrolling interest in subsidiaries held by parties other
than the parent be clearly identified, labeled, and presented in
the consolidated statement of financial position within equity,
but separate from the parents equity, that the amount of
consolidated net income attributable to the parent and to the
noncontrolling interest be clearly identified and presented on
the face of the consolidated statement of income, that the
changes in a parents ownership interest while the parent
retains its controlling financial interest in its subsidiary be
accounted for consistently as equity transactions and that when
a subsidiary is deconsolidated, any retained noncontrolling
equity investment in the former subsidiary be initially measured
at fair value. This statement is effective for fiscal years
beginning after December 15, 2008. Accordingly, the Company
adopted SFAS No. 160 as of January 1, 2009. The
adoption of SFAS No. 160 has changed the presentation
of noncontrolling interests on our income statement, balance
sheet and changes in shareholders equity. Refer to
Note 8 for the additional disclosures related to changes in
shareholders equity.
Disclosures about derivative instruments and hedging
activities: In March 2008, the FASB issued
SFAS No. 161 Disclosures about Derivative
Instruments and Hedging Activities an amendment of
FASB Statement No. 133, which requires enhanced
disclosures about derivative and hedging activities. Companies
are required to provide enhanced disclosures about (a) how
and why a company uses derivative instruments, (b) how
derivative instruments and related hedged items are accounted
for under SFAS No. 133 and related interpretations,
and (c) how derivative instruments and related hedged items
affect the companys financial position, financial
performance, and cash flows. SFAS No. 161 is effective
for financial statements issued for fiscal and interim periods
beginning after November 15, 2008. Accordingly, the Company
adopted SFAS No. 161 as of January 1, 2009. Refer
to Note 7 for the enhanced disclosures related to the
Companys derivative instruments.
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating
Securities: In June 2008, the FASB issued FSP
EITF 03-6-1
Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating Securities, which
addresses whether unvested instruments granted in share-based
payment transactions that contain nonforfeitable rights to
dividends or dividend equivalents are
6
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
participating securities subject to the two-class method of
computing earnings per share under SFAS No. 128,
Earnings Per Share. FSP
EITF 03-6-1
is effective for financial statements issued for fiscal years
beginning after December 15, 2008 and interim periods
within those years. The Company adopted FSP
EITF 03-6-1 January 1,
2009. FSP
EITF 03-6-1
did not result in a change in the Companys earnings per
share or diluted earnings per share upon its adoption.
Determination of the Useful Life of Intangible
Assets: In April 2008, the FASB issued
FSP 142-3,
Determination of the Useful Life of Intangible
Assets, which amends SFAS No. 142,
Goodwill and Other Intangible Assets
(SFAS No. 142), regarding the factors that should be
considered in developing the useful lives for intangible assets
with renewal or extension provisions. FSP
FAS 142-3
requires an entity to consider its own historical experience in
renewing or extending similar arrangements, regardless of
whether those arrangements have explicit renewal or extension
provisions, when determining the useful life of an intangible
asset. In the absence of such experience, an entity shall
consider the assumptions that market participants would use
about renewal or extension, adjusted for entity-specific
factors. FSP
FAS 142-3
is effective for qualifying intangible assets acquired by the
Company on or after January 1, 2009. The application of FSP
FAS 142-3
did not have a material impact on the Companys results of
operations, cash flows or financial position upon adoption;
however, future transactions entered into by the Company will
need to be evaluated under the requirements of this FSP.
Employers Disclosures about Postretirement Benefit Plan
Assets: In December 2008, the FASB issued FSP
FAS No. 132(R)-1, Employers Disclosures
about Postretirement Benefit Plan Assets (FSP
FAS 132(R)-1), which requires additional disclosures for
employers pension and other postretirement benefit plan
assets. Disclosures regarding fair value measurements of pension
and other postretirement benefit plan assets were not included
within the scope of SFAS No. 157. FSP
FAS 132(R)-1 requires employers to disclose information
about fair value measurements of plan assets that would be
similar to the disclosures about fair value measurements
required under SFAS No. 157, the investment policies
and strategies for the major categories of plan assets, and
significant concentrations of risk within plan assets. FSP
FAS 132(R)-1 will be effective for the Company as of
December 31, 2009. As FSP FAS 132(R)-1 provides only
disclosure requirements, the adoption of this standard will not
have a material impact on the Companys results of
operations, cash flows or financial positions.
Fair Value of Financial Instruments: In April
2009, the FASB issued FSP
FAS 107-1
and Accounting Principles Board (APB)
No. 28-1,
Interim Disclosures about Fair Value of Financial
Instruments, which requires disclosures about fair value
of financial instruments for interim reporting periods as well
as in annual financial statements. The FSP also amends APB
No. 28, Interim Financial Reporting, to
require those disclosures in summarized financial information at
interim reporting periods. FSP
FAS 107-1
requires that an entity disclose in the body or in the
accompanying notes of its financial information the fair value
of all financial instruments for which it is practicable to
estimate that value, whether recognized or not recognized in the
statement of financial position, as required by Statement 107.
In addition, an entity shall also disclose the method(s) and
significant assumptions used to estimate the fair value of
financial instruments.
FSP
FAS 107-1
is effective for interim reporting periods ending after
June 15, 2009, with early adoption permitted for periods
ending after March 15, 2009. FSP
FAS 107-1
does not require disclosures for earlier periods presented for
comparative purposes at initial adoption. In periods after
initial adoption, this FSP requires comparative disclosures only
for periods ending after initial adoption. The Company is
currently evaluating the provisions of FSP
FAS 107-1
and does not expect the adoption to have a material impact on
the Companys results of operations, cash flows or
financial position.
Determining Fair Value When the Volume and Level of Activity
for the Asset or Liability Have Significantly Decreased and
Identifying Transactions That Are Not Orderly: In
April 2009, the FASB issued FSP
FAS 157-4
Determining Fair Value When the Volume and Level of
Activity for the Asset or Liability Have Significantly Decreased
and Identifying Transactions That Are Not Orderly. FSP
FAS 157-4
provides additional guidance for estimating fair value in
accordance with SFAS No. 157, Fair Value Measurements,
when the volume and level of
7
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
activity for the asset or liability have significantly
decreased. FSP
FAS 157-4
also includes guidance on identifying circumstances that
indicate a transaction is not orderly.
FSP
FAS 157-4
is effective for interim and annual reporting periods ending
after June 15, 2009, and shall be applied prospectively.
Early adoption is permitted for periods ending after
March 15, 2009. FSP
FAS 157-4
does not require disclosures for earlier periods presented for
comparative purposes at initial adoption. In periods after
initial adoption, comparative disclosures are required but only
for periods ending after initial adoption. The Company is
currently evaluating the provisions of FSP
FAS 157-4
and does not expect the adoption to have a material impact on
the Companys results of operations, cash flows or
financial position.
Integration
of Arrow
In connection with the acquisition of Arrow International, Inc.
(Arrow) in October 2007, the Company formulated a
plan related to the future integration of Arrow and the
Companys Medical businesses. The integration plan focuses
on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing, and
distribution functions in North America, Europe and Asia. The
Company finalized its estimate of the costs to implement the
plan in the fourth quarter of 2008. The Company has accrued
estimates for certain costs, related primarily to personnel
reductions and facility closures and the termination of certain
distribution agreements at the date of acquisition, in
accordance with EITF Issue
No. 95-3,
Recognition of Liabilities in Connection with a Purchase
Business Combination.
The following table provides information relating to changes in
the accrued liability associated with the Arrow integration plan
during the three months ended March 29, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Adjustments to
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
|
2008
|
|
|
Reserve
|
|
|
Payments
|
|
|
Translation
|
|
|
2009
|
|
|
|
(Dollars in millions)
|
|
|
Termination benefits
|
|
$
|
4.3
|
|
|
$
|
(0.3
|
)
|
|
$
|
(0.1
|
)
|
|
$
|
|
|
|
$
|
3.9
|
|
Facility closure costs
|
|
|
0.8
|
|
|
|
|
|
|
|
|
|
|
|
(0.1
|
)
|
|
|
0.7
|
|
Contract termination costs
|
|
|
4.8
|
|
|
|
0.3
|
|
|
|
(1.8
|
)
|
|
|
(0.4
|
)
|
|
|
2.9
|
|
Other integration costs
|
|
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
10.6
|
|
|
$
|
|
|
|
$
|
(1.9
|
)
|
|
$
|
(0.5
|
)
|
|
$
|
8.2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
It is anticipated that a majority of these costs will be paid in
2009; however, some portions of the contract termination costs
for leased facilities may extend to 2013.
In conjunction with the plan for the integration of Arrow and
the Companys Medical businesses, the Company has taken
actions that affect employees and facilities of Teleflex. This
aspect of the integration plan is explained in Note 4
Restructuring and costs incurred for this aspect of
the plan will be charged to earnings and included in
restructuring and other impairment charges within
the condensed consolidated statement of operations.
8
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The amounts recognized in restructuring and other impairment
charges for the three months ended March 29, 2009 and
March 30, 2008 consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2008 Commercial Segment program
|
|
$
|
1,138
|
|
|
$
|
|
|
2007 Arrow integration program
|
|
|
1,325
|
|
|
|
8,046
|
|
2006 restructuring program
|
|
|
|
|
|
|
810
|
|
|
|
|
|
|
|
|
|
|
Restructuring and other impairment charges
|
|
$
|
2,463
|
|
|
$
|
8,856
|
|
|
|
|
|
|
|
|
|
|
2008
Commercial Segment Program
In December 2008, the Company began certain restructuring
initiatives with respect to the Companys Commercial
Segment. These initiatives involve the consolidation of
operations and a related reduction in workforce at certain of
the Companys facilities in North America and Europe. The
Company has determined to undertake these initiatives as a means
to address an expected continuation of weakness in the marine
and industrial markets.
The charges associated with the 2008 Commercial Segment
restructuring program that are included in restructuring and
other impairment charges during the three months ended
March 29, 2009 were as follows:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
|
Commercial
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,138
|
|
|
|
|
|
|
|
|
$
|
1,138
|
|
|
|
|
|
|
The following table provides information relating to changes in
the accrued liability associated with the 2008 Commercial
Segment restructuring program during the three months ended
March 29, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
|
2008
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2009
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
449
|
|
|
$
|
1,138
|
|
|
$
|
(297
|
)
|
|
$
|
(4
|
)
|
|
$
|
1,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
449
|
|
|
$
|
1,138
|
|
|
$
|
(297
|
)
|
|
$
|
(4
|
)
|
|
$
|
1,286
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 29, 2009, the Company expects to incur the
following restructuring expenses associated with the 2008
Commercial Segment restructuring program over the next three
quarters:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Termination benefits
|
|
$
|
1.1 1.4
|
|
Facility closure costs
|
|
|
0.7 0.9
|
|
Contract termination costs
|
|
|
0.2 0.4
|
|
|
|
|
|
|
|
|
$
|
2.0 2.7
|
|
|
|
|
|
|
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2008
Commercial Segment restructuring program. Facility closure costs
related primarily to costs that will
9
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
be incurred to prepare a facility for closure. Contract
termination costs related primarily to the termination of leases
in conjunction with the consolidation of facilities.
2007
Arrow Integration Program
In connection with the acquisition of Arrow, the Company
formulated a plan related to the future integration of Arrow and
the Companys Medical businesses. The integration plan
focuses on the closure of Arrow corporate functions and the
consolidation of manufacturing, sales, marketing, and
distribution functions in North America, Europe and Asia. In as
much as the actions affect employees and facilities of Arrow,
the resultant costs have been included in the allocation of the
purchase price of Arrow. Costs related to actions that affect
employees and facilities of Teleflex will be charged to earnings
and included in restructuring and other impairment
charges within the consolidated statement of operations.
The charges associated with the 2007 Arrow integration program
that are included in restructuring and other impairment charges
during the three months ended March 29, 2009 and
March 30, 2008, were as follows:
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
1,097
|
|
|
$
|
8,046
|
|
Facility closure costs
|
|
|
51
|
|
|
|
|
|
Contract termination costs
|
|
|
62
|
|
|
|
|
|
Other restructuring costs
|
|
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,325
|
|
|
$
|
8,046
|
|
|
|
|
|
|
|
|
|
|
The following table provides information relating to changes in
the accrued liability associated with the 2007 Arrow integration
program during the three months ended March 29, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
|
|
|
|
December 31,
|
|
|
Subsequent
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
|
2008
|
|
|
Accruals
|
|
|
Payments
|
|
|
Translation
|
|
|
2009
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
7,815
|
|
|
$
|
1,097
|
|
|
$
|
(1,987
|
)
|
|
$
|
(466
|
)
|
|
$
|
6,459
|
|
Facility closure costs
|
|
|
601
|
|
|
|
51
|
|
|
|
(64
|
)
|
|
|
(38
|
)
|
|
|
550
|
|
Contract termination costs
|
|
|
|
|
|
|
62
|
|
|
|
(45
|
)
|
|
|
|
|
|
|
17
|
|
Other restructuring costs
|
|
|
159
|
|
|
|
115
|
|
|
|
(113
|
)
|
|
|
(12
|
)
|
|
|
149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
8,575
|
|
|
$
|
1,325
|
|
|
$
|
(2,209
|
)
|
|
$
|
(516
|
)
|
|
$
|
7,175
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination benefits are comprised of severance-related payments
for all employees terminated in connection with the 2007 Arrow
integration program. Facility closure costs related primarily to
costs that will be incurred to prepare a facility for closure.
Contract termination costs related primarily to the termination
of leases in conjunction with the consolidation of facilities.
10
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
As of March 29, 2009, the Company expects to incur the
following restructuring expenses associated with the 2007 Arrow
integration program in its Medical Segment over the next two
years:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Termination benefits
|
|
$
|
5.0 6.0
|
|
Facility closure costs
|
|
|
0.8 1.0
|
|
Contract termination costs
|
|
|
8.5 9.0
|
|
Other restructuring costs
|
|
|
1.5 2.0
|
|
|
|
|
|
|
|
|
$
|
15.8 18.0
|
|
|
|
|
|
|
2006
Restructuring Program
In June 2006, the Company began certain restructuring
initiatives that affected all three of the Companys
reporting segments. These initiatives involved the consolidation
of operations and a related reduction in workforce at several of
the Companys facilities in Europe and North America. The
Company determined to undertake these initiatives as a means to
improving operating performance and to better leverage the
Companys existing resources.
For the three months ended March 30, 2008, the charges
associated with the 2006 restructuring program that are included
in restructuring and other impairment charges were as follows:
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 30, 2008
|
|
|
|
Medical
|
|
|
|
(Dollars in thousands)
|
|
|
Termination benefits
|
|
$
|
771
|
|
Contract termination costs
|
|
|
39
|
|
|
|
|
|
|
|
|
$
|
810
|
|
|
|
|
|
|
Termination benefits were comprised of severance-related
payments for all employees terminated in connection with the
2006 restructuring program. Contract termination costs related
primarily to the termination of leases in conjunction with the
consolidation of facilities. As of March 29, 2009 the
Company does not expect to incur additional restructuring
expenses associated with the 2006 restructuring program. The
accrued liability at March 29, 2009 and December 31,
2008 was nominal.
Inventories consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Raw materials
|
|
$
|
180,497
|
|
|
$
|
185,270
|
|
Work-in-process
|
|
|
60,709
|
|
|
|
55,618
|
|
Finished goods
|
|
|
199,713
|
|
|
|
221,281
|
|
|
|
|
|
|
|
|
|
|
|
|
|
440,919
|
|
|
|
462,169
|
|
Less: Inventory reserve
|
|
|
(34,090
|
)
|
|
|
(37,516
|
)
|
|
|
|
|
|
|
|
|
|
Inventories
|
|
$
|
406,829
|
|
|
$
|
424,653
|
|
|
|
|
|
|
|
|
|
|
11
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 6
|
Goodwill
and other intangible assets
|
Changes in the carrying amount of goodwill, by operating
segment, for the three months ended March 29, 2009 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
|
(Dollars in thousands)
|
|
|
Goodwill at December 31, 2008
|
|
$
|
1,428,679
|
|
|
$
|
6,317
|
|
|
$
|
39,127
|
|
|
$
|
1,474,123
|
|
Adjustment to acquisition balance sheet
|
|
|
(525
|
)
|
|
|
|
|
|
|
|
|
|
|
(525
|
)
|
Dispositions
|
|
|
|
|
|
|
(268
|
)
|
|
|
|
|
|
|
(268
|
)
|
Translation adjustment
|
|
|
(25,497
|
)
|
|
|
|
|
|
|
(828
|
)
|
|
|
(26,325
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill at March 29, 2009
|
|
$
|
1,402,657
|
|
|
$
|
6,049
|
|
|
$
|
38,299
|
|
|
$
|
1,447,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
|
Accumulated Amortization
|
|
|
|
March 29,
|
|
|
December 31,
|
|
|
March 29,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Customer lists
|
|
$
|
548,961
|
|
|
$
|
553,786
|
|
|
$
|
54,281
|
|
|
$
|
48,311
|
|
Intellectual property
|
|
|
218,813
|
|
|
|
221,549
|
|
|
|
56,860
|
|
|
|
53,437
|
|
Distribution rights
|
|
|
22,737
|
|
|
|
26,833
|
|
|
|
15,911
|
|
|
|
16,422
|
|
Trade names
|
|
|
329,373
|
|
|
|
333,495
|
|
|
|
1,042
|
|
|
|
875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
1,119,884
|
|
|
$
|
1,135,663
|
|
|
$
|
128,094
|
|
|
$
|
119,045
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense related to intangible assets was
approximately $11.1 million and $11.7 million for the
three months ended March 29, 2009 and March 30, 2008,
respectively. Estimated annual amortization expense for each of
the five succeeding years is as follows (dollars in thousands):
|
|
|
|
|
2009
|
|
$
|
45,000
|
|
2010
|
|
|
45,000
|
|
2011
|
|
|
44,600
|
|
2012
|
|
|
43,600
|
|
2013
|
|
|
42,300
|
|
|
|
Note 7
|
Financial
instruments
|
The Company uses derivative instruments for risk management
purposes. Forward rate contracts are used to manage foreign
currency transaction exposure and interest rate swaps are used
to reduce exposure to interest rate changes. In accordance with
SFAS No. 133, these derivative instruments are
designated as cash flow hedges and are recorded on the balance
sheet at fair market value. The effective portion of the gains
or losses on derivatives are reported as a component of other
comprehensive income and reclassified into earnings in the same
period or periods during which the hedged transaction affects
earnings. Gains and losses on the derivative representing either
hedge ineffectiveness or hedge components excluded from the
assessment of effectiveness are recognized in current earnings.
The fair value of the interest rate swap contracts is developed
from market-based inputs under the income approach using cash
flows discounted at relevant market interest rates. The fair
value of the foreign currency forward exchange contracts
represents the amount required to enter into offsetting
contracts with similar remaining maturities based on quoted
market prices. See Note 11, Fair Value
Measurement for additional information.
12
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The location and fair values of derivative instruments
designated as hedging instruments under SFAS No. 133
in the balance sheet are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Values of Derivative Instruments
|
|
|
|
Asset Derivatives
|
|
|
Liability Derivatives
|
|
|
|
As of March 29, 2009
|
|
|
|
Balance Sheet Location
|
|
Fair Value
|
|
|
Balance Sheet Location
|
|
Fair Value
|
|
|
|
(Dollars in thousands)
|
|
|
Interest rate contracts
|
|
|
|
$
|
|
|
|
Derivative liabilities current
|
|
$
|
14,322
|
|
Interest rate contracts
|
|
|
|
|
|
|
|
Other liabilities noncurrent
|
|
|
25,404
|
|
Foreign exchange contracts
|
|
Other assets current
|
|
|
992
|
|
|
Derivative liabilities current
|
|
|
8,650
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total derivatives
|
|
|
|
$
|
992
|
|
|
|
|
$
|
48,376
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The location and amount of the gains and losses for derivatives
in SFAS No. 133 cash flow hedging relationships that
were reported in other comprehensive income (OCI),
accumulated other comprehensive income (AOCI) and
the income statement are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective Portion
|
|
|
|
Gain (Loss)
|
|
|
|
|
|
|
Recognized in
|
|
|
|
|
|
|
OCI
|
|
|
Loss Reclassified from AOCI into Income
|
|
|
|
After Tax Amount
|
|
|
Location
|
|
Pre-Tax Amount
|
|
|
|
As of March 29, 2009
|
|
|
|
(Dollars in thousands)
|
|
|
Interest rate contracts
|
|
$
|
3,098
|
|
|
Interest expense
|
|
$
|
4,357
|
|
Foreign exchange contracts
|
|
|
1,683
|
|
|
Net revenues
|
|
|
859
|
|
Foreign exchange contracts
|
|
|
|
|
|
Materials, labor and other product costs
|
|
|
1,616
|
|
Foreign exchange contracts
|
|
|
|
|
|
Income from discontinued operations
|
|
|
277
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
4,781
|
|
|
|
|
$
|
7,109
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended March 29, 2009, there was no
ineffectiveness related to the Companys derivatives.
13
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 8
|
Changes
in shareholders equity
|
The following tables summarize the activity in
shareholders equity for the three months ended
March 29, 2009 and March 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-
|
|
|
Equity-
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Noncontrolling
|
|
|
Comprehensive
|
|
|
|
Total Equity
|
|
|
Shareholders
|
|
|
Interest
|
|
|
Income
|
|
|
|
(Dollars in thousands)
|
|
|
Balance as of December 31, 2008
|
|
$
|
1,285,883
|
|
|
$
|
1,246,455
|
|
|
$
|
39,428
|
|
|
|
|
|
Net income
|
|
|
225,607
|
|
|
|
215,511
|
|
|
|
10,096
|
|
|
$
|
225,607
|
|
Cash dividends ($0.34 per share)
|
|
|
(13,511
|
)
|
|
|
(13,511
|
)
|
|
|
|
|
|
|
|
|
Financial instruments marked to market, net of tax of $1,541
|
|
|
4,781
|
|
|
|
4,781
|
|
|
|
|
|
|
|
4,781
|
|
Cumulative translation adjustment (CTA)
|
|
|
(46,443
|
)
|
|
|
(46,344
|
)
|
|
|
(99
|
)
|
|
|
(46,443
|
)
|
Reclassification of CTA to gain
|
|
|
(9,365
|
)
|
|
|
(9,365
|
)
|
|
|
|
|
|
|
(9,365
|
)
|
Pension liability adjustment, net of tax of $498
|
|
|
1,061
|
|
|
|
1,061
|
|
|
|
|
|
|
|
1,061
|
|
Disposition of noncontrolling interest
|
|
|
(45,019
|
)
|
|
|
|
|
|
|
(45,019
|
)
|
|
|
|
|
Shares issued under compensation plans
|
|
|
2,398
|
|
|
|
2,398
|
|
|
|
|
|
|
|
|
|
Distributions to noncontrolling interest shareholders
|
|
|
(295
|
)
|
|
|
|
|
|
|
(295
|
)
|
|
|
|
|
Deferred compensation
|
|
|
343
|
|
|
|
343
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 29, 2009
|
|
$
|
1,405,440
|
|
|
$
|
1,401,329
|
|
|
$
|
4,111
|
|
|
$
|
175,641
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity-
|
|
|
Equity-
|
|
|
|
|
|
|
|
|
|
Common
|
|
|
Noncontrolling
|
|
|
Comprehensive
|
|
|
|
Total Equity
|
|
|
Shareholders
|
|
|
Interest
|
|
|
Income
|
|
|
|
(Dollars in thousands)
|
|
|
Balance as of December 31, 2007
|
|
$
|
1,371,026
|
|
|
$
|
1,328,843
|
|
|
$
|
42,183
|
|
|
|
|
|
Net income
|
|
|
29,997
|
|
|
|
22,943
|
|
|
|
7,054
|
|
|
$
|
29,997
|
|
Split-dollar life insurance arrangements adjustment
|
|
|
(2,189
|
)
|
|
|
(2,189
|
)
|
|
|
|
|
|
|
(2,189
|
)
|
Cash dividends ($0.32 per share)
|
|
|
(12,622
|
)
|
|
|
(12,622
|
)
|
|
|
|
|
|
|
|
|
Financial instruments marked to market, net of tax of $7,143
|
|
|
(11,642
|
)
|
|
|
(11,642
|
)
|
|
|
|
|
|
|
(11,642
|
)
|
Cumulative translation adjustment
|
|
|
26,012
|
|
|
|
26,022
|
|
|
|
(10
|
)
|
|
|
26,012
|
|
Pension liability adjustment, net of tax of $261
|
|
|
(423
|
)
|
|
|
(423
|
)
|
|
|
|
|
|
|
(423
|
)
|
Disposition of noncontrolling interest
|
|
|
804
|
|
|
|
|
|
|
|
804
|
|
|
|
|
|
Shares issued under compensation plans
|
|
|
5,192
|
|
|
|
5,192
|
|
|
|
|
|
|
|
|
|
Distributions to noncontrolling interest shareholders
|
|
|
(12,692
|
)
|
|
|
|
|
|
|
(12,692
|
)
|
|
|
|
|
Deferred compensation
|
|
|
332
|
|
|
|
332
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at March 30, 2008
|
|
$
|
1,393,795
|
|
|
$
|
1,356,456
|
|
|
$
|
37,339
|
|
|
$
|
41,755
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Set forth below is a reconciliation of the Companys issued
common shares:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Shares in thousands)
|
|
|
Common shares, beginning of period
|
|
|
41,995
|
|
|
|
41,794
|
|
Shares issued under compensation plans
|
|
|
10
|
|
|
|
76
|
|
|
|
|
|
|
|
|
|
|
Common shares, end of period
|
|
|
42,005
|
|
|
|
41,870
|
|
Less: Treasury shares, end of period
|
|
|
2,256
|
|
|
|
2,275
|
|
|
|
|
|
|
|
|
|
|
Outstanding shares, end of period
|
|
|
39,749
|
|
|
|
39,595
|
|
|
|
|
|
|
|
|
|
|
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the Board authorization may be made from time to time in
the open market and may include privately-negotiated
transactions as market conditions warrant and subject to
regulatory considerations. The stock repurchase program has no
expiration date and the Companys ability to execute on the
program will depend on, among other factors, cash requirements
for acquisitions, cash generation from operations, debt
repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into October 1, 2007, the Company is subject to
certain restrictions relating to its ability to repurchase
shares in the event the Companys consolidated leverage
ratio exceeds certain levels, which may further limit the
Companys ability to repurchase shares under this Board
authorization. Through March 29, 2009, no shares have been
purchased under this Board authorization.
Basic earnings per share is computed by dividing net income by
the weighted average number of common shares outstanding during
the period. Diluted earnings per share is computed in the same
manner except that the weighted average number of shares is
increased for dilutive securities. The difference between basic
and diluted weighted average common shares results from the
assumption that dilutive share-based payment awards were
exercised or vested at the beginning of the period. A
reconciliation of basic to diluted weighted average shares
outstanding is as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Shares in thousands)
|
|
|
Basic
|
|
|
39,692
|
|
|
|
39,454
|
|
Dilutive shares assumed issued
|
|
|
184
|
|
|
|
255
|
|
|
|
|
|
|
|
|
|
|
Diluted
|
|
|
39,876
|
|
|
|
39,709
|
|
|
|
|
|
|
|
|
|
|
Weighted average stock options that were antidilutive and
therefore not included in the calculation of earnings per share
were approximately 1,483 thousand and 938 thousand for the three
months ended March 29, 2009 and March 30, 2008,
respectively.
|
|
Note 9
|
Stock
compensation plans
|
The Company has two stock-based compensation plans under which
equity-based awards may be made. The Companys 2000 Stock
Compensation Plan (the 2000 plan) provides for the
granting of incentive and non-qualified stock options and
restricted stock units to directors, officers and key employees.
Under the 2000 plan, the Company is authorized to issue up to
4 million shares of common stock, but no more than 800,000
of those shares may be issued as restricted stock. Options
granted under the 2000 plan have an exercise price equal to the
average of the high and low sales prices of the Companys
common stock on the date of the grant, rounded to the nearest
$0.25. Generally, options granted under the 2000 plan are
exercisable three to five years after the date of the grant and
15
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
expire no more than ten years after the grant. Outstanding
restricted stock units generally vest in one to three years.
During the first three months of 2009, the Company granted
restricted stock units representing 152,319 shares of
common stock under the 2000 plan.
The Companys 2008 Stock Incentive Plan (the 2008
plan) provides for the granting of various types of
equity-based awards to directors, officers and key employees.
These awards include incentive and non-qualified stock options,
stock appreciation rights, stock awards and other stock-based
awards. Under the 2008 plan, the Company is authorized to issue
up to 2.5 million shares of common stock, but grants of
awards other than stock options and stock appreciation rights
may not exceed 875,000 shares. Options granted under the
2008 plan have an exercise price equal to the closing price of
the Companys common stock on the date of grant. During the
first three months of 2009, the Company granted incentive and
non-qualified options to purchase 448,144 shares of common
stock under the 2008 plan.
|
|
Note 10
|
Pension
and other postretirement benefits
|
The Company has a number of defined benefit pension and
postretirement plans covering eligible U.S. and
non-U.S. employees.
The defined benefit pension plans are noncontributory. The
benefits under these plans are based primarily on years of
service and employees pay near retirement. The
Companys funding policy for U.S. plans is to
contribute annually, at a minimum, amounts required by
applicable laws and regulations. Obligations under
non-U.S. plans
are systematically provided for by depositing funds with
trustees or by book reserves.
In 2008, the Company took the following actions with respect to
its pension benefits:
|
|
|
|
|
Effective August 31, 2008, the Arrow Salaried plan, the
Arrow Hourly plan and the Berks plan were merged into the
Teleflex Retirement Income Plan (TRIP).
|
|
|
|
On October 31, 2008, the TRIP was amended to cease future
benefit accruals for all non-bargained employees as of
December 31, 2008.
|
|
|
|
On December 15, 2008, the Company amended its Supplemental
Executive Retirement Plans (SERP) for all executives
to cease future benefit accruals as of December 31, 2008.
In addition, the Company approved a plan to replace the
non-qualified defined benefits provided under the SERP with a
non-qualified defined contribution arrangement under the
Companys Deferred Compensation Plan, effective
January 1, 2009.
|
In addition, on October 31, 2008, the Companys
postretirement benefit plans were amended to eliminate future
benefits for non-bargained employees who had not attained
age 50 or whose age plus service was less than 65.
The Company and certain of its subsidiaries provide medical,
dental and life insurance benefits to pensioners and survivors.
The associated plans are unfunded and approved claims are paid
from Company funds.
Net benefit cost of pension and postretirement benefit plans
consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
Other Benefits
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Service cost
|
|
$
|
915
|
|
|
$
|
1,641
|
|
|
$
|
284
|
|
|
$
|
247
|
|
Interest cost
|
|
|
4,150
|
|
|
|
3,984
|
|
|
|
900
|
|
|
|
747
|
|
Expected return on plan assets
|
|
|
(3,538
|
)
|
|
|
(5,470
|
)
|
|
|
|
|
|
|
|
|
Net amortization and deferral
|
|
|
1,235
|
|
|
|
471
|
|
|
|
220
|
|
|
|
266
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net benefit cost
|
|
$
|
2,762
|
|
|
$
|
626
|
|
|
$
|
1,404
|
|
|
$
|
1,260
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
Note 11
|
Fair
value measurement
|
The Company adopted SFAS No. 157 for financial assets
and financial liabilities as of January 1, 2008, in
accordance with the provisions of SFAS No. 157 and the
related guidance of
FSP 157-1,
FSP 157-2
and
FSP 157-3.
The adoption did not have an impact on the Companys
financial position and results of operations. The Company
endeavors to utilize the best available information in measuring
fair value. The Company has determined the fair value of its
financial assets based on Level 1 and Level 2 inputs
and the fair value of its financial liabilities based on
Level 2 inputs in accordance with the fair value hierarchy
described as follows:
Valuation
Hierarchy
SFAS No. 157 establishes a valuation hierarchy of the
inputs used to measure fair value. This hierarchy prioritizes
the inputs into three broad levels as follows:
Level 1 inputs quoted prices (unadjusted) in
active markets for identical assets or liabilities that the
Company has ability to access at the measurement date.
Level 2 inputs inputs other than quoted prices
included within Level 1 that are observable for the asset
or liability, either directly or indirectly. If the asset or
liability has a specified (contractual) term, a Level 2
input must be observable for substantially the full term of the
asset or liability. Level 2 inputs include:
1. Quoted prices for similar assets or liabilities in
active markets.
2. Quoted prices for identical or similar assets or
liabilities in markets that are not active or there are few
transactions.
3. Inputs other than quoted prices that are observable for
the asset or liability.
4. Inputs that are derived principally from or corroborated
by observable market data by correlation or other means.
Level 3 inputs unobservable inputs for the
asset or liability. Unobservable inputs may be used to measure
fair value only when observable inputs are not available.
Unobservable inputs reflect the Companys assumptions about
the assumptions market participants would use in pricing the
asset or liability in achieving the fair value measurement
objective of an exit price perspective.
A financial asset or liabilitys classification within the
hierarchy is determined based on the lowest level input that is
significant to the fair value measurement.
The following tables provide the financial assets and
liabilities carried at fair value measured on a recurring basis
as of March 29, 2009 and March 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total carrying
|
|
|
Quoted prices in
|
|
|
Significant other
|
|
|
Significant
|
|
|
|
Value at
|
|
|
active markets
|
|
|
observable inputs
|
|
|
unobservable inputs
|
|
|
|
March 29, 2009
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
|
(Dollars in thousands)
|
|
|
Cash and cash equivalents
|
|
$
|
30,000
|
|
|
$
|
30,000
|
|
|
$
|
|
|
|
$
|
|
|
Deferred compensation assets
|
|
$
|
2,233
|
|
|
$
|
2,233
|
|
|
$
|
|
|
|
$
|
|
|
Derivative assets
|
|
$
|
992
|
|
|
$
|
|
|
|
$
|
992
|
|
|
$
|
|
|
Derivative liabilities
|
|
$
|
48,376
|
|
|
$
|
|
|
|
$
|
48,376
|
|
|
$
|
|
|
17
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total carrying
|
|
|
Quoted prices in
|
|
|
Significant other
|
|
|
Significant
|
|
|
|
Value at
|
|
|
active markets
|
|
|
observable inputs
|
|
|
unobservable inputs
|
|
|
|
March 30, 2008
|
|
|
(Level 1)
|
|
|
(Level 2)
|
|
|
(Level 3)
|
|
|
|
(Dollars in thousands)
|
|
|
Deferred compensation assets
|
|
$
|
3,706
|
|
|
$
|
3,706
|
|
|
$
|
|
|
|
$
|
|
|
Derivative assets
|
|
$
|
1,378
|
|
|
$
|
|
|
|
$
|
1,378
|
|
|
$
|
|
|
Derivative liabilities
|
|
$
|
34,675
|
|
|
$
|
|
|
|
$
|
34,675
|
|
|
$
|
|
|
Valuation
Techniques
The Companys cash and cash equivalents valued based upon
Level 1 inputs are comprised of overnight investments in
money market funds. The funds invest in obligations of the U.S.
Treasury, including Treasury bills, bonds and notes. The funds
seek to maintain a net asset value of $1.00 per share.
The Companys financial assets valued based upon
Level 1 inputs are comprised of investments in marketable
securities held in Rabbi Trusts which are used to fund benefits
under certain deferred compensation plans. Under these deferred
compensation plans, participants designate investment options to
serve as the basis for measurement of the notional value of
their accounts. The investment assets of the rabbi trust are
valued using quoted market prices multiplied by the number of
shares held in the trust.
The Companys financial assets valued based upon
Level 2 inputs are comprised of foreign currency forward
contracts. The Companys financial liabilities valued based
upon Level 2 inputs are comprised of an interest rate swap
contract and foreign currency forward contracts. The Company has
taken into account the creditworthiness of the counterparties in
measuring fair value. The Company uses forward rate contracts to
manage currency transaction exposure and interest rate swaps to
manage exposure to interest rate changes. The fair value of the
interest rate swap contract is developed from market-based
inputs under the income approach using cash flows discounted at
relevant market interest rates. The fair value of the foreign
currency forward exchange contracts represents the amount
required to enter into offsetting contracts with similar
remaining maturities based on quoted market prices.
|
|
Note 12
|
Commitments
and contingent liabilities
|
Product warranty liability: The Company
warrants to the original purchaser of certain of its products
that it will, at its option, repair or replace, without charge,
such products if they fail due to a manufacturing defect.
Warranty periods vary by product. The Company has recourse
provisions for certain products that would enable recovery from
third parties for amounts paid under the warranty. The Company
accrues for product warranties when, based on available
information, it is probable that customers will make claims
under warranties relating to products that have been sold, and a
reasonable estimate of the costs (based on historical claims
experience relative to sales) can be made. Set forth below is a
reconciliation of the Companys estimated product warranty
liability for the three months ended March 29, 2009
(dollars in thousands):
|
|
|
|
|
Balance December 31, 2008
|
|
$
|
17,106
|
|
Accruals for warranties issued in 2009
|
|
|
2,706
|
|
Settlements (cash and in kind)
|
|
|
(2,226
|
)
|
Accruals related to pre-existing warranties
|
|
|
(162
|
)
|
Dispositions
|
|
|
(75
|
)
|
Effect of translation
|
|
|
(384
|
)
|
|
|
|
|
|
Balance March 29, 2009
|
|
$
|
16,965
|
|
|
|
|
|
|
Operating leases: The Company uses various
leased facilities and equipment in its operations. The terms for
these leased assets vary depending on the lease agreement. In
connection with these operating leases, the Company
18
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
had residual value guarantees in the amount of approximately
$1.9 million at March 29, 2009. The Companys
future payments under the operating leases cannot exceed the
minimum rent obligation plus the residual value guarantee
amount. The guarantee amounts are tied to the unamortized lease
values of the assets under lease, and are due if the Company
declines to renew the leases or to exercise its purchase option
with respect to the leased assets. At March 29, 2009, the
Company had no liabilities recorded for these obligations. Any
residual value guarantee amounts paid to the lessor may be
recovered by the Company from the sale of the assets to a third
party.
Accounts receivable securitization program: We
use an accounts receivable securitization program to gain access
to enhanced credit markets and reduce financing costs. As
currently structured, accounts receivable of certain domestic
subsidiaries are sold on a non-recourse basis to a special
purpose entity (SPE), which is a bankruptcy-remote
subsidiary of Teleflex Incorporated that is consolidated in our
financial statements. This SPE then sells undivided interests in
those receivables to an asset backed commercial paper conduit.
The conduit issues notes secured by those interests and other
assets to third party investors.
To the extent that cash consideration is received for the sale
of undivided interests in the receivables by the SPE to the
conduit, it is accounted for as a sale in accordance with
SFAS No. 140, Accounting for Transfers and
Servicing of Financial Assets and Extinguishments of
Liabilities, as we have relinquished control of the
receivables. Accordingly, undivided interests in accounts
receivable sold to the commercial paper conduit under these
transactions are excluded from accounts receivables, net in the
accompanying consolidated balance sheets. The interests not
represented by cash consideration from the conduit are retained
by the SPE and remain in accounts receivable in the accompanying
consolidated balance sheets.
The interests in receivables sold and the interest in
receivables retained by the SPE are carried at face value, which
is due to the short-term nature of our accounts receivable. The
special purpose entity has received cash consideration of
$39.7 million and $39.7 million for the interests in
the accounts receivable it has sold to the commercial paper
conduit at March 29, 2009 and December 31, 2008,
respectively. No gain or loss is recorded upon sale as fee
charges from the commercial paper conduit are based upon a
floating yield rate and the period the undivided interests
remain outstanding. Fee charges from the commercial paper
conduit are accrued at the end of each month. Should we default
under the accounts receivable securitization program, the
commercial paper conduit is entitled to receive collections on
receivables owned by the SPE in satisfaction of the amount of
cash consideration paid to the SPE to the commercial paper
conduit. The assets of the SPE are not available to satisfy the
obligations of Teleflex or any of its other subsidiaries.
Information regarding the outstanding balances related to the
SPEs interests in accounts receivables sold or retained as
of March 29, 2009 is as follows:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Interests in receivables sold
outstanding(1)
|
|
$
|
39.7
|
|
Interests in receivables retained, net of allowance for doubtful
accounts
|
|
$
|
98.7
|
|
|
|
|
(1) |
|
Deducted from accounts receivables, net in the condensed
consolidated balance sheets. |
The delinquency ratio for the qualifying receivables represented
4.8% of the total qualifying receivables as of March 29,
2009.
The following table summarizes the activity related to our
interests in accounts receivable sold for the three months ended
March 29, 2009:
|
|
|
|
|
|
|
(Dollars in millions)
|
|
|
Proceeds from the sale of interest in accounts receivable
|
|
$
|
39.7
|
|
Fees and
charges(1)
|
|
$
|
0.3
|
|
|
|
|
(1) |
|
Recorded in interest expense in the condensed consolidated
statement of operations. |
19
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Other fee charges related to the sale of receivables to the
commercial paper conduit for the three month period ended
March 29, 2009 were not material.
We continue servicing the receivables sold, pursuant to
servicing agreements with the SPE. No servicing asset is
recorded at the time of sale because we do not receive any
servicing fees from third parties or other income related to the
servicing of the receivables. We do not record any servicing
liability at the time of the sale as the receivables collection
period is relatively short and the costs of servicing the
receivables sold over the servicing period are insignificant.
Servicing costs are recognized as incurred over the servicing
period.
Environmental: The Company is subject to
contingencies as a result of environmental laws and regulations
that in the future may require the Company to take further
action to correct the effects on the environment of prior
disposal practices or releases of chemical or petroleum
substances by the Company or other parties. Much of this
liability results from the U.S. Comprehensive Environmental
Response, Compensation and Liability Act (CERCLA),
often referred to as Superfund, the U.S. Resource
Conservation and Recovery Act (RCRA) and similar
state laws. These laws require the Company to undertake certain
investigative and remedial activities at sites where the Company
conducts or once conducted operations or at sites where
Company-generated waste was disposed.
Remediation activities vary substantially in duration and cost
from site to site. These activities, and their associated costs,
depend on the mix of unique site characteristics, evolving
remediation technologies, diverse regulatory agencies and
enforcement policies, as well as the presence or absence of
other potentially responsible parties. At March 29, 2009,
the Companys condensed consolidated balance sheet included
an accrued liability of approximately $9.1 million relating
to these matters. Considerable uncertainty exists with respect
to these costs and, if adverse changes in circumstances occur,
potential liability may exceed the amount accrued as of
March 29, 2009. The time frame over which the accrued
amounts may be paid out, based on past history, is estimated to
be
15-20 years.
Regulatory matters: On October 11, 2007,
the Companys subsidiary, Arrow International, Inc.
(Arrow), received a corporate warning letter from
the U.S. Food and Drug Administration (FDA). The letter
cites three site-specific warning letters issued by the FDA in
2005 and subsequent inspections performed from June 2005 to
February 2007 at Arrows facilities in the United States.
The letter expresses concerns with Arrows quality systems,
including complaint handling, corrective and preventive action,
process and design validation, inspection and training
procedures. It also advises that Arrows corporate-wide
program to evaluate, correct and prevent quality system issues
has been deficient. Limitations on pre-market approvals and
certificates for foreign governments had previously been imposed
on Arrow based on prior inspections and the corporate warning
letter did not impose additional sanctions that are expected to
have a material financial impact on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company developed an integration plan
that included the commitment of significant resources to correct
these previously-identified regulatory issues and further
improve overall quality systems. Senior management officials
from the Company have met with FDA representatives, and a
comprehensive written corrective action plan was presented to
FDA in late 2007. The Company has completed implementation of
the corrective actions under the plan and is awaiting
re-inspection by the FDA.
While the Company believes it has substantially remediated these
issues through the corrective actions taken to date, there can
be no assurances that these issues have been resolved to the
satisfaction of the FDA. If the Companys remedial actions
are not satisfactory to the FDA, the Company may have to devote
additional financial and human resources to its efforts, and the
FDA may take further regulatory actions against the Company,
including, but not limited to, seizing its product inventory,
obtaining a court injunction against further marketing of the
Companys products or assessing civil monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company held a 60% economic interest, approximately
$10.5 million for customs duty and approximately
$67 million for value added tax (VAT).
20
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Subsequent to these initial assessments, HMRC has substantially
reduced the assessments for customs duties to $50,693 and for
VAT to $310,932. In connection with the sale of the
Companys ownership interest in Airfoil Technologies
International Singapore Pte. Ltd. to GE Pacific
Private Ltd., which was completed in March 2009, General
Electric Company agreed to assume
ATI-UKs
liabilities, including the customs duties and VAT liabilities
described above.
Litigation: The Company is a party to various
lawsuits and claims arising in the normal course of business.
These lawsuits and claims include actions involving product
liability, intellectual property, employment and environmental
matters. Based on information currently available, advice of
counsel, established reserves and other resources, the Company
does not believe that any such actions are likely to be,
individually or in the aggregate, material to its business,
financial condition, results of operations or liquidity.
However, in the event of unexpected further developments, it is
possible that the ultimate resolution of these matters, or other
similar matters, if unfavorable, may be materially adverse to
the Companys business, financial condition, results of
operations or liquidity. Legal costs such as outside counsel
fees and expenses are charged to expense in the period incurred.
Other: The Company has various purchase
commitments for materials, supplies and items of permanent
investment incident to the ordinary conduct of business. On
average, such commitments are not at prices in excess of current
market.
|
|
Note 13
|
Business
segment information
|
Information about continuing operations by business segment is
as follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Segment data:
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
340,542
|
|
|
$
|
374,057
|
|
Aerospace
|
|
|
43,729
|
|
|
|
66,288
|
|
Commercial
|
|
|
85,404
|
|
|
|
101,765
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
|
469,675
|
|
|
|
542,110
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
|
70,193
|
|
|
|
70,912
|
|
Aerospace
|
|
|
3,037
|
|
|
|
4,928
|
|
Commercial
|
|
|
4,661
|
|
|
|
2,847
|
|
|
|
|
|
|
|
|
|
|
Segment operating
profit(1)
|
|
|
77,891
|
|
|
|
78,687
|
|
Less: Corporate expenses
|
|
|
10,767
|
|
|
|
13,008
|
|
Net loss on sales of businesses and assets
|
|
|
2,597
|
|
|
|
18
|
|
Restructuring and impairment charges
|
|
|
2,463
|
|
|
|
8,856
|
|
Noncontrolling interest
|
|
|
(236
|
)
|
|
|
(187
|
)
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before interest and taxes
|
|
$
|
62,300
|
|
|
$
|
56,992
|
|
|
|
|
|
|
|
|
|
|
21
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Identifiable
assets(2):
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
3,078,879
|
|
|
$
|
3,135,360
|
|
Aerospace
|
|
|
155,099
|
|
|
|
244,994
|
|
Commercial
|
|
|
206,258
|
|
|
|
215,894
|
|
Corporate
|
|
|
358,265
|
|
|
|
322,286
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,798,501
|
|
|
$
|
3,918,534
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Segment operating profit includes a segments net revenues
reduced by its materials, labor and other product costs along
with the segments selling, engineering and administrative
expenses and noncontrolling interest. Unallocated corporate
expenses, (gain) loss on sales of assets, restructuring and
impairment charges, interest income and expense and taxes on
income are excluded from the measure. |
|
(2) |
|
Identifiable assets do not include assets held for sale of $7.8
and $8.2 million in 2009 and 2008, respectively. |
|
|
Note 14
|
Divestiture-related
activities
|
As dispositions occur in the normal course of business, gains or
losses on the sale of such businesses are recognized in the
income statement line item Net loss on sales of
businesses and assets.
The following table provides the amount of Net loss on sales
of businesses and assets for the three months ended
March 29, 2009 and March 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Net loss on sales of businesses and assets
|
|
$
|
2,597
|
|
|
$
|
18
|
|
During the first quarter of 2009, the Company realized a loss of
$2.6 million on the sale of a product line in its Marine
business.
Assets
Held for Sale
Assets held for sale at March 29, 2009 and
December 31, 2008 consists of four buildings which the
Company is actively marketing.
Discontinued
Operations
On March 20, 2009, the Company completed the sale of its
51 percent share of Airfoil Technologies
International Singapore Pte. Ltd. (ATI
Singapore) to GE Pacific Private Limited for
$300 million in cash. ATI Singapore, which provides engine
repair products and services for critical components of flight
turbines, was part of a joint venture between General Electric
Company (GE) and the Company. The Company and GE are
also parties to an agreement that will permit the Company to
transfer its ownership interest in the remaining ATI business
(together with ATI Singapore, the ATI Business) to
GE by the end of 2009.
The Companys condensed consolidated statement of income
for the three months ended March 30, 2008 has been
retrospectively adjusted to reflect the operations of the ATI
Business which was part of the Companys Aerospace Segment
as discontinued.
22
TELEFLEX
INCORPORATED AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Concluded)
The results of these discontinued operations for the three
months ended March 29, 2009 and March 30, 2008 were as
follows:
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Net revenues
|
|
$
|
67,721
|
|
|
$
|
62,410
|
|
Costs and other expenses
|
|
|
(45,533
|
)
|
|
|
(47,215
|
)
|
Gain on disposition
|
|
|
275,787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations before income taxes
|
|
|
297,975
|
|
|
|
15,195
|
|
Provision for income taxes
|
|
|
99,018
|
|
|
|
406
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations
|
|
|
198,957
|
|
|
|
14,789
|
|
Less: Income from discontinued operations attributable to
noncontrolling interest
|
|
|
9,860
|
|
|
|
6,867
|
|
|
|
|
|
|
|
|
|
|
Income from discontinued operations attributable to common
shareholders
|
|
$
|
189,097
|
|
|
$
|
7,922
|
|
|
|
|
|
|
|
|
|
|
Net assets and liabilities sold in relation to the ATI Business
comprised the following:
|
|
|
|
|
|
|
March 29, 2009
|
|
|
|
(Dollars in thousands)
|
|
|
Net assets
|
|
$
|
101,052
|
|
Net liabilities
|
|
|
(67,474
|
)
|
|
|
|
|
|
|
|
$
|
33,578
|
|
|
|
|
|
|
23
|
|
Item 2.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations
|
Forward-Looking
Statements
All statements made in this Quarterly Report on
Form 10-Q,
other than statements of historical fact, are forward-looking
statements. The words anticipate,
believe, estimate, expect,
intend, may, plan,
will, would, should,
guidance, potential,
continue, project, forecast,
confident, prospects, and similar
expressions typically are used to identify forward-looking
statements. Forward-looking statements are based on the
then-current expectations, beliefs, assumptions, estimates and
forecasts about our business and the industry and markets in
which we operate. These statements are not guarantees of future
performance and are subject to risks, uncertainties and
assumptions which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is
expressed or implied by these forward-looking statements due to
a number of factors, including changes in business relationships
with and purchases by or from major customers or suppliers,
including delays or cancellations in shipments; demand for and
market acceptance of new and existing products; our ability to
integrate acquired businesses into our operations, realize
planned synergies and operate such businesses profitably in
accordance with expectations; our ability to effectively execute
our restructuring programs; competitive market conditions and
resulting effects on revenues and pricing; increases in raw
material costs that cannot be recovered in product pricing; and
global economic factors, including currency exchange rates and
interest rates; difficulties entering new markets; and general
economic conditions. For a further discussion of the risks
relating to our business, see Item 1A of our Annual Report
on
Form 10-K
for the fiscal year ended December 31, 2008. We expressly
disclaim any obligation to update these forward-looking
statements, except as otherwise specifically stated by us or as
required by law or regulation.
Overview
Teleflex strives to maintain a portfolio of businesses that
provide consistency of performance, improved profitability and
sustainable growth. Over the past several years, we
significantly changed the composition of our portfolio through
acquisitions and divestitures to improve margins, reduce
cyclicality and focus our resources on the development of our
core businesses.
On March 20, 2009, we completed the sale of our
51 percent share of Airfoil Technologies
International Singapore Pte. Ltd. (ATI
Singapore) to GE Pacific Private Limited for
$300 million in cash. We recognized a gain of approximately
$179 million, net of $97 million of taxes in
discontinued operations. We are also party to an agreement with
GE that will permit the Company to transfer its ownership
interest in the remaining ATI business (together with ATI
Singapore, the ATI Business) to GE by the end of
2009. We used $240 million of the proceeds to repay
long-term debt. (See Note 14 to our condensed consolidated
financial statements included in this report for discussion of
discontinued operations).
We are focused on achieving consistent and sustainable growth
through our internal growth initiatives which include the
development of new products, expansion of market share, moving
existing products into new geographies, and through selected
acquisitions which enhance or expedite our development
initiatives and our ability to increase market share. We
continually evaluate the composition of the portfolio of our
businesses to ensure alignment with our overall objectives.
The Medical, Aerospace and Commercial segments comprised 73%, 9%
and 18% of our revenues, respectively, for the three months
ended March 29, 2009 and comprised 69%, 12% and 19% of our
revenues, respectively, for the same period in 2008.
Critical
Accounting Estimates
Preparation of our financial statements requires management to
make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. We believe the
most complex and sensitive judgments, because of their
significance to the Consolidated Financial Statements, result
primarily from the need to make estimates about the effects of
matters that are inherently uncertain. Managements
Discussion and Analysis and Note 1 to the Consolidated
Financial Statements included in our Annual Report on
Form 10-K
for the fiscal year ended December 31, 2008 describe the
significant accounting estimates and policies used in
preparation of the
24
Consolidated Financial Statements. Actual results in these areas
could differ from managements estimates. There have been
no significant changes in our critical accounting estimates
during the first three months of 2009.
Results
of Operations
Discussion of growth from acquisitions reflects the impact of a
purchased company for up to twelve months beyond the date of
acquisition. Activity beyond the initial twelve months is
considered core growth. Core growth excludes the impact of
translating the results of international subsidiaries at
different currency exchange rates from year to year and the
comparable activity of divested companies within the most recent
twelve-month period.
The following comparisons exclude the impact of the operations
of the ATI Business which has been presented in our consolidated
financial results as discontinued operations (see Note 14
to our condensed consolidated financial statements included in
this report for discussion of discontinued operations).
Revenues
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
Net revenues
|
|
$
|
469.7
|
|
|
$
|
542.1
|
|
Net revenues decreased approximately 13% to $469.7 million
from $542.1 million in 2008. Foreign currency translation
caused 5% of the decline in revenue, while revenues from core
business declined 8% compared to 2008. We experienced declines
in core revenue in each of our three segments, Medical (4%),
Aerospace (27%) and Commercial (13%). The weak global economic
environment negatively impacted the markets served by our
Aerospace and Commercial Segments and core growth in the Medical
Segment was negatively impacted by distributor inventory
reductions, lower demand for respiratory care products in North
America due to a less severe flu season compared to 2008 and a
decline in orthopedic devices sold to medical Original Equipment
Manufacturers, or OEMs.
Gross
profit
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
Gross profit
|
|
$
|
196.1
|
|
|
$
|
213.4
|
|
Percentage of sales
|
|
|
41.8
|
%
|
|
|
39.4
|
%
|
Gross profit as a percentage of revenues increased to 41.8% in
2009 from 39.4% in 2008. While each of our three segments
reported higher gross profit as a percentage of revenues, the
principal factor impacting the overall increase was a higher
percentage of Medical revenues and a $7 million fair value
adjustment to inventory in the first quarter of 2008 related to
inventory acquired in the Arrow acquisition, which did not recur
in 2009.
Selling,
engineering and administrative
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
Selling, engineering and administrative
|
|
$
|
128.8
|
|
|
$
|
147.6
|
|
Percentage of sales
|
|
|
27.4
|
%
|
|
|
27.2
|
%
|
Selling, engineering and administrative expenses (operating
expenses) as a percentage of revenues were 27.4% in 2009
compared to 27.2% in 2008. The reduction in these costs were
principally the result of movements in currency exchange rates
of approximately $4 million and approximately
$10 million due to cost reduction initiatives including
restructuring and integration activities in connection with the
Arrow acquisition.
25
Interest
expense
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
Interest expense
|
|
$
|
25.4
|
|
|
$
|
31.1
|
|
Average interest rate on debt
|
|
|
5.68
|
%
|
|
|
6.39
|
%
|
Interest expense decreased in the first quarter of 2009 compared
to the same period of a year ago due to a combination of
approximately $100 million lower debt outstanding during
the period and to lower interest rates.
Taxes on
income from continuing operations
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
Effective income tax rate
|
|
|
28.2
|
%
|
|
|
43.4
|
%
|
The effective income tax rate for the three months ended
March 29, 2009 was 28.2% versus 43.4% for the three months
ended March 30, 2008. The principal factors affecting the
comparison of the effective income tax rate for the respective
periods are the beneficial effects of a change in the population
of loss making entities under FIN 18 in 2009, a smaller
impact from discrete tax charges in 2009 compared to 2008 and a
higher benefit related to foreign income inclusions in 2009
compared to 2008.
Restructuring
and other impairment charges
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
|
(Dollars in millions)
|
|
|
2008 Commercial restructuring program
|
|
$
|
1.2
|
|
|
$
|
|
|
2007 Arrow integration program
|
|
|
1.3
|
|
|
|
8.0
|
|
2006 restructuring programs
|
|
|
|
|
|
|
0.8
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2.5
|
|
|
$
|
8.8
|
|
|
|
|
|
|
|
|
|
|
In December 2008, we began certain restructuring initiatives
that affect the Commercial Segment. These initiatives involve
the consolidation of operations and a related reduction in
workforce at three of our facilities in Europe and North
America. We determined to undertake these initiatives to improve
operating performance and to better leverage our existing
resources. These costs amounted to approximately
$1.2 million during the first quarter of 2009. As of
March 29, 2009, we estimate that we will incur
$2.0 $2.7 million in restructuring charges
during the remainder of 2009 in connection with this program. Of
this amount, $1.1 $1.4 million relates to
employee termination costs, $0.7 $0.9 million
to facility closure costs and $0.2 $0.4 million
to contract termination costs, primarily relating to leases. We
expect to realize annual pre-tax savings of between
$3.5 $4.5 million in 2010 when these
restructuring actions are complete.
In connection with the acquisition of Arrow in 2007, we
formulated a plan related to the future integration of Arrow and
our other Medical businesses. The integration plan focuses on
the closure of Arrow corporate functions and the consolidation
of manufacturing, sales, marketing, and distribution functions
in North America, Europe and Asia. Costs related to actions that
affect employees and facilities of Arrow have been included in
the allocation of the purchase price of Arrow. Costs related to
actions that affect employees and facilities of Teleflex are
charged to earnings and included in restructuring and impairment
charges within the consolidated statement of operations. These
costs amounted to approximately $1.3 million during the
first quarter of 2009. As of March 29, 2009, we estimate
that, for the remainder of 2009 and 2010, the aggregate of
future restructuring and impairment charges that we will incur
in connection with the Arrow integration plan are approximately
$15.8 $18.0 million. Of this amount,
$5.0 $6.0 million relates to employee
termination costs, $0.8 $1.0 million relates to
facility closure costs, $8.5 $9.0 million
relates to contract termination costs associated with the
termination of leases and certain distribution agreements and
$1.5 $2.0 million relates to other
restructuring costs. We also have incurred
26
restructuring related costs in the Medical Segment which do not
qualify for classification as restructuring costs. In 2009 these
costs amounted to $0.6 million and are reported in the
Medical Segments operating results in selling, engineering
and administrative expenses. We expect to have realized annual
pre-tax savings of between $70 $75 million in
2010 when these integration and restructuring actions are
complete.
In June 2006, we began certain restructuring initiatives that
affected all three of our operating segments. These initiatives
involved the consolidation of operations and a related reduction
in workforce at several of our facilities in Europe and North
America. We took these initiatives as a means to improving
operating performance and to better leverage our existing
resources. These activities are now complete.
For additional information regarding our restructuring programs,
see Note 4 to our consolidated financial statements
included in this report.
Segment
Reviews
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
|
|
|
|
% Increase/
|
|
|
|
March 29, 2009
|
|
|
March 30, 2008
|
|
|
(Decrease)
|
|
|
|
(Dollars in thousands)
|
|
|
Medical
|
|
$
|
340,542
|
|
|
$
|
374,057
|
|
|
|
(9
|
)
|
Aerospace
|
|
|
43,729
|
|
|
|
66,288
|
|
|
|
(34
|
)
|
Commercial
|
|
|
85,404
|
|
|
|
101,765
|
|
|
|
(16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment net revenues
|
|
$
|
469,675
|
|
|
$
|
542,110
|
|
|
|
(13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
|
|
$
|
70,193
|
|
|
$
|
70,912
|
|
|
|
(1
|
)
|
Aerospace
|
|
|
3,037
|
|
|
|
4,928
|
|
|
|
(38
|
)
|
Commercial
|
|
|
4,661
|
|
|
|
2,847
|
|
|
|
64
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment operating
profit(1)
|
|
$
|
77,891
|
|
|
$
|
78,687
|
|
|
|
(1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 13 of our condensed consolidated financial
statements for a reconciliation of segment operating profit to
income from continuing operations before interest and taxes. |
The percentage increases (decreases) in net revenues during the
three months ended March 29, 2009 compared to the same
period in 2008 are due to the following factors:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Increase/(Decrease)
|
|
|
|
2009 vs. 2008
|
|
|
|
Medical
|
|
|
Aerospace
|
|
|
Commercial
|
|
|
Total
|
|
|
Core growth
|
|
|
(4
|
)
|
|
|
(27
|
)
|
|
|
(13
|
)
|
|
|
(8
|
)
|
Currency impact
|
|
|
(5
|
)
|
|
|
(7
|
)
|
|
|
(3
|
)
|
|
|
(5
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Change
|
|
|
(9
|
)
|
|
|
(34
|
)
|
|
|
(16
|
)
|
|
|
(13
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a discussion of our segment operating results.
Comparison
of the three months ended March 29, 2009 and March 30,
2008
Medical
Medical Segment net revenues declined 9% in the first quarter of
2009 to $340.5 million, from $374.1 million in the
same period last year. Foreign currency fluctuations caused 5%
of the revenue decline and 4% was due to a decline in core
revenue. The decline in core revenue was predominantly in the
North American critical care, cardiac care and OEM orthopedic
instrumentation product groups.
27
Net sales by product group are comprised of the following.
Certain reclassifications within product groups have been made
to 2008 amounts to conform with the current year presentation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
% Increase/(Decrease)
|
|
|
|
March 29,
|
|
|
March 30,
|
|
|
Core
|
|
|
Currency
|
|
|
Total
|
|
|
|
2009
|
|
|
2008
|
|
|
Growth
|
|
|
Impact
|
|
|
Change
|
|
|
|
(Dollars in millions)
|
|
|
Critical Care
|
|
$
|
218.1
|
|
|
$
|
243.7
|
|
|
|
(5
|
)
|
|
|
(6
|
)
|
|
|
(11
|
)
|
Surgical
|
|
|
69.0
|
|
|
|
72.9
|
|
|
|
1
|
|
|
|
(6
|
)
|
|
|
(5
|
)
|
Cardiac Care
|
|
|
15.4
|
|
|
|
18.2
|
|
|
|
(10
|
)
|
|
|
(5
|
)
|
|
|
(15
|
)
|
OEM
|
|
|
34.2
|
|
|
|
36.3
|
|
|
|
(4
|
)
|
|
|
(2
|
)
|
|
|
(6
|
)
|
Other
|
|
|
3.8
|
|
|
|
3.0
|
|
|
|
46
|
|
|
|
(19
|
)
|
|
|
27
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Sales
|
|
$
|
340.5
|
|
|
$
|
374.1
|
|
|
|
(4
|
)
|
|
|
(5
|
)
|
|
|
(9
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Segment net revenues for the three months ended
March 29, 2009 and March 30, 2008, respectively are
geographically comprised of the following:
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
North America
|
|
|
55
|
%
|
|
|
54
|
%
|
Europe, Middle East and Africa
|
|
|
35
|
%
|
|
|
37
|
%
|
Asia and Latin America
|
|
|
10
|
%
|
|
|
9
|
%
|
The decrease in critical care product sales during the first
quarter of 2009 compared to the same period in 2008 was due to a
decline of core revenue in North America of approximately
$12 million, principally due to distributor destocking and
in respiratory care due to a less severe flu season compared to
2008, and to approximately $13 million from changes in
foreign currency exchange rates.
Surgical product core revenue growth in Europe and
Asia/Latin
America of approximately $2 million was more than offset by
the impact of foreign currency rate movements.
Sales credits issued to customers in connection with a voluntary
recall of certain intra aortic balloon pump catheters during the
first quarter of 2009 was the principal factor in the decrease
in sales of Cardiac Care products.
Lower sales to OEMs during the quarter were largely attributable
to lower sales of orthopedic instrumentation products as core
growth in specialty suture products was offset by changes in
foreign currency exchange rates.
Operating profit in the Medical Segment decreased 1%, from
$70.9 million to $70.2 million, during the first
quarter. The negative impact on operating profit from lower
revenues and a stronger US dollar was largely offset by
approximately $5 million lower selling, general and
administrative costs during the current period as a result of
cost reduction intiatives, including restructuring and
integration activities in connection with the Arrow acquisition.
Also, a $7 million expense for fair value adjustment to
inventory in the first quarter of 2008 related to inventory
acquired in the Arrow acquisition, which did not recur in 2009,
had a favorable impact on the first quarter of 2009 operating
profit comparison to the prior year period.
Aerospace
Aerospace Segment revenues declined 34% in the first quarter of
2009 to $43.7 million, from $66.3 million in the same
period last year. Lower sales of wide body cargo handling
systems caused by delays in delivery schedules by aircraft
manufacturers, a lower number of cargo system conversions in the
aftermarket and lower demand for cargo containers from
commercial airlines and freight companies due to the current
weakness in the commercial aviation sector were the principal
factors driving the 27% decline in core revenue during the
quarter.
Segment operating profit decreased 38% in the first quarter of
2009, from $4.9 million to $3.0 million, principally
due to the lower sales volumes, including reduced sales of
higher margin spares and the stronger US dollar.
28
Commercial
Commercial Segment revenues declined approximately 16% in the
first quarter of 2009 to $85.4 million, from
$101.8 million in the same period last year. Core revenue
declined 13% as a result of a 33% decline in sales of marine
products for the recreational boat market which was partially
offset by higher sales of auxiliary power units for the North
American truck market. Weakness in global economic conditions
continues to adversely impact the markets served by our
Commercial businesses.
During the first quarter of 2009, operating profit in the
Commercial Segment increased 64%, from $2.8 million to
$4.7 million in spite of the decline in sales, principally
due to the elimination of approximately $4 million of
operating costs during the quarter.
Liquidity
and Capital Resources
Operating activities from continuing operations used net cash of
approximately $4 million during the first three months of
2009. Changes in our operating assets and liabilities of
$65 million during the first three months of 2009 is
primarily due to increases in accounts receivable and inventory
of $13 million and $12 million, respectively and a
decrease in trade payables of $18 million and accrued
expenses of $18 million reflecting a reduction in payroll
related costs and interest. The increase in accounts receivable
is largely attributable to the European Medical business where
we have experienced a slightly slower paying pattern from our
customers, which we believe is a result of the current economic
environment, to our Marine business related to entering the peak
season and to large aircraft manufacturers extending payment
terms. The lower than expected demand for respiratory care
products in North America due to a less severe than
expected flu season drove $7 million of higher inventory,
and delays by aircraft manufacturers in delivery schedules for
our wide body cargo handling systems caused an additional
$3 million increase in inventory. Tax payments related to
the sale of the ATI Business of approximately $93 million
are expected to be made in the second quarter of 2009.
Our financing activities from continuing operations during the
first three months of 2009 consisted primarily of payment of
$240 million in long-term borrowings from the proceeds of
the sale of the ATI Business to GE and payment of dividends of
$14 million. Cash flows provided by our investing
activities from continuing operations during the first three
months of 2009 consisted primarily of the proceeds from the sale
of the ATI Business and $7 million of capital expenditures.
We use an accounts receivable securitization program to gain
access to enhanced credit markets and reduce financing costs. As
currently structured, accounts receivable of certain domestic
subsidiaries are sold on a
non-recourse
basis to a special purpose entity (SPE), which is a
bankruptcy-remote subsidiary of Teleflex Incorporated that is
consolidated in our financial statements. This SPE then sells
undivided interests in those receivables to an asset backed
commercial paper conduit. The conduit issues notes secured by
those interests and other assets to third party investors.
To the extent that cash consideration is received for the sale
of undivided interests in the receivables by the SPE to the
conduit, it is accounted for as a sale in accordance with
SFAS No. 140, Accounting for Transfers and
Servicing of Financial Assets and Extinguishments of
Liabilities, as we have relinquished control of the
receivables. Accordingly, undivided interests in accounts
receivable sold to the commercial paper conduit under these
transactions are excluded from accounts receivables, net in the
accompanying consolidated balance sheets. The interests not
represented by cash consideration from the conduit are retained
by the SPE and remain in accounts receivable in the accompanying
consolidated balance sheets.
The interests in receivables sold and the interest in
receivables retained by the SPE are carried at face value, which
is due to the short-term nature of our accounts receivable. The
special purpose entity has received cash consideration of
$39.7 million and $39.7 million for the interests in
the accounts receivable it has sold to the commercial paper
conduit at March 29, 2009 and December 31, 2008,
respectively. No gain or loss is recorded upon sale as fee
charges from the commercial paper conduit are based upon a
floating yield rate and the period the undivided interests
remain outstanding. Fee charges from the commercial paper
conduit are accrued at the end of each month. Should we default
under the accounts receivable securitization program, the
commercial paper conduit is entitled to receive collections on
receivables owned by the SPE in satisfaction of the amount of
cash consideration
29
paid to the SPE to the commercial paper conduit. The assets of
the SPE are not available to satisfy the obligations of Teleflex
or any of its other subsidiaries.
On June 14, 2007, the Companys Board of Directors
authorized the repurchase of up to $300 million of
outstanding Company common stock. Repurchases of Company stock
under the Board authorization may be made from time to time in
the open market and may include privately-negotiated
transactions as market conditions warrant and subject to
regulatory considerations. The stock repurchase program has no
expiration date and the Companys ability to execute on the
program will depend on, among other factors, cash requirements
for acquisitions, cash generation from operations, debt
repayment obligations, market conditions and regulatory
requirements. In addition, under the senior loan agreements
entered into October 1, 2007, the Company is subject to
certain restrictions relating to its ability to repurchase
shares in the event the Companys consolidated leverage
ratio exceeds certain levels, which may further limit the
Companys ability to repurchase shares under this Board
authorization. Through March 29, 2009, no shares have been
purchased under this Board authorization.
The following table provides our net debt to total capital ratio:
|
|
|
|
|
|
|
|
|
|
|
March 29,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
(Dollars in thousands)
|
|
|
Net debt includes:
|
|
|
|
|
|
|
|
|
Current borrowings
|
|
$
|
5,973
|
|
|
$
|
108,853
|
|
Long-term borrowings
|
|
|
1,299,662
|
|
|
|
1,437,538
|
|
|
|
|
|
|
|
|
|
|
Total debt
|
|
|
1,305,635
|
|
|
|
1,546,391
|
|
Less: Cash and cash equivalents
|
|
|
143,051
|
|
|
|
107,275
|
|
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,162,584
|
|
|
$
|
1,439,116
|
|
|
|
|
|
|
|
|
|
|
Total capital includes:
|
|
|
|
|
|
|
|
|
Net debt
|
|
$
|
1,162,584
|
|
|
$
|
1,439,116
|
|
Total common shareholders equity
|
|
|
1,401,329
|
|
|
|
1,246,455
|
|
|
|
|
|
|
|
|
|
|
Total capital
|
|
$
|
2,563,913
|
|
|
$
|
2,685,571
|
|
|
|
|
|
|
|
|
|
|
Percent of net debt to total capital
|
|
|
45
|
%
|
|
|
54
|
%
|
Our current borrowings have decreased significantly during the
first quarter of 2009 because we repaid $240 million of
debt from the proceeds of the sale of the ATI Business,
$153 million of which were scheduled principal payments
through June 30, 2010 on our term loan.
The Senior Credit Facility and the senior note agreements
contain covenants that, among other things, limit or restrict
our ability, and the ability of our subsidiaries, to incur debt,
create liens, consolidate, merge or dispose of certain assets,
make certain investments, engage in acquisitions, pay dividends
on, repurchase or make distributions in respect of capital stock
and enter into swap agreements. These agreements also require us
to maintain a consolidated leverage ratio (defined in the Senior
Credit Facility as Consolidated Leverage Ratio) and
an interest coverage ratio (defined in the Senior Credit
Facility as Consolidated Interest Coverage Ratio) at
the levels and as of the last day of any period of four
consecutive fiscal quarters ending on or nearest to the dates
set forth in the table below calculated pursuant to the
definitions and methodology set forth in the Senior Credit
Facility.
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Interest
|
|
|
|
Consolidated Leverage Ratio
|
|
|
Coverage Ratio
|
|
Fiscal Quarter Ending on or Nearest to
|
|
Must be Less Than
|
|
|
Actual
|
|
|
Must be More Than
|
|
|
Actual
|
|
|
December 31, 2007
|
|
|
4.75:1
|
|
|
|
3.80:1
|
|
|
|
3.00:1
|
|
|
|
3.46:1
|
|
March 31, 2008
|
|
|
4.75:1
|
|
|
|
3.84:1
|
|
|
|
3.00:1
|
|
|
|
3.51:1
|
|
June 30, 2008
|
|
|
4.75:1
|
|
|
|
3.71:1
|
|
|
|
3.00:1
|
|
|
|
3.58:1
|
|
September 30, 2008
|
|
|
4.75:1
|
|
|
|
3.43:1
|
|
|
|
3.00:1
|
|
|
|
3.78:1
|
|
December 31, 2008
|
|
|
4.00:1
|
|
|
|
3.29:1
|
|
|
|
3.50:1
|
|
|
|
4.04:1
|
|
March 31, 2009
|
|
|
4.00:1
|
|
|
|
3.13:1
|
|
|
|
3.50:1
|
|
|
|
4.16:1
|
|
June 30, 2009
|
|
|
4.00:1
|
|
|
|
|
|
|
|
3.50:1
|
|
|
|
|
|
September 30, 2009 and at all times thereafter
|
|
|
3.50:1
|
|
|
|
|
|
|
|
3.50:1
|
|
|
|
|
|
As of March 29, 2009, the aggregate amount of debt maturing
for each year is as follows (dollars in millions):
|
|
|
|
|
2009
|
|
$
|
6.0
|
|
2010
|
|
|
51.2
|
|
2011
|
|
|
247.2
|
|
2012
|
|
|
769.7
|
|
2013
|
|
|
|
|
2014 and thereafter
|
|
|
231.5
|
|
We believe that our cash flow from operations and our ability to
access additional funds through credit facilities will enable us
to fund our operating requirements and capital expenditures and
meet debt obligations. As of March 29, 2009, the Company
had no borrowings outstanding under its $400 million
revolving credit facility.
Goodwill
Since we performed our annual goodwill impairment review in
2008, our market capitalization has declined 38% as of
March 29, 2009. However, our market capitalization
continues to exceed our book value and there have been no
significant changes in the underlying businesses. Accordingly,
we do not believe there have been any events or circumstances
that would require us to perform an interim goodwill impairment
review.
However, due to the ongoing uncertainty in market conditions,
which may negatively impact the performance of our reporting
units, we will continue to monitor and evaluate the carrying
values of our goodwill. If market and economic conditions or our
units business performance deteriorates significantly,
this could result in our performance of interim impairment
reviews. Any such impairment reviews could result in recognition
of a goodwill impairment charge in 2009 or thereafter.
|
|
Item 3.
|
Quantitative
and Qualitative Disclosures About Market Risk
|
There have been no significant changes in market risk for the
quarter ended March 29, 2009. See the information set forth
in Part II, Item 7A of the Companys Annual
Report on
Form 10-K
for the fiscal year ended December 31, 2008.
31
|
|
Item 4.
|
Controls
and Procedures
|
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of the end of the
period covered by this report. Based on that evaluation, the
Chief Executive Officer and Chief Financial Officer concluded
that our disclosure controls and procedures as of the end of the
period covered by this report are functioning effectively to
provide reasonable assurance that the information required to be
disclosed by us in reports filed under the Securities Exchange
Act of 1934 is (i) recorded, processed, summarized and
reported within the time periods specified in the SECs
rules and forms and (ii) accumulated and communicated to
our management, including the Chief Executive Officer and Chief
Financial Officer, as appropriate to allow timely decisions
regarding disclosure. A controls system cannot provide absolute
assurance that the objectives of the controls system are met,
and no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within a
company have been detected.
(b) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting
occurred during our most recent fiscal quarter that has
materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
32
PART II
OTHER INFORMATION
Item 1. Legal
Proceedings
On October 11, 2007, the Companys subsidiary, Arrow
International, Inc. (Arrow), received a corporate
warning letter from the U.S. Food and Drug Administration
(FDA). The letter cites three site-specific warning letters
issued by the FDA in 2005 and subsequent inspections performed
from June 2005 to February 2007 at Arrows facilities in
the United States. The letter expresses concerns with
Arrows quality systems, including complaint handling,
corrective and preventive action, process and design validation,
inspection and training procedures. It also advises that
Arrows corporate-wide program to evaluate, correct and
prevent quality system issues has been deficient. Limitations on
pre-market approvals and certificates for foreign governments
had previously been imposed on Arrow based on prior inspections
and the corporate warning letter did not impose additional
sanctions that are expected to have a material financial impact
on the Company.
In connection with its acquisition of Arrow, completed on
October 1, 2007, the Company developed an integration plan
that included the commitment of significant resources to correct
these previously-identified regulatory issues and further
improve overall quality systems. Senior management officials
from the Company have met with FDA representatives, and a
comprehensive written corrective action plan was presented to
FDA in late 2007. The Company has completed implementation of
the corrective actions under the plan and is awaiting
re-inspection by the FDA.
While the Company believes it has substantially remediated these
issues through the corrective actions taken to date, there can
be no assurances that these issues have been resolved to the
satisfaction of the FDA. If the Companys remedial actions
are not satisfactory to the FDA, the Company may have to devote
additional financial and human resources to its efforts, and the
FDA may take further regulatory actions against the Company,
including, but not limited to, seizing its product inventory,
obtaining a court injunction against further marketing of the
Companys products or assessing civil monetary penalties.
In June 2008, HM Revenue and Customs (HMRC) assessed
Airfoil Technologies International UK Limited
(ATI-UK), a consolidated United Kingdom venture in
which the Company held a 60% economic interest, approximately
$10.5 million for customs duty and approximately
$67 million for value added tax (VAT).
Subsequent to these initial assessments, HMRC has substantially
reduced the assessments for customs duties to $50,693 and for
VAT to $310,932. In connection with the sale of the
Companys ownership interest in Airfoil Technologies
International Singapore Pte. Ltd. to GE Pacific
Private Ltd., which was completed in March 2009, General
Electric Company agreed to assume
ATI-UKs
liabilities, including the customs duties and VAT liabilities
described above.
In addition, we are a party to various lawsuits and claims
arising in the normal course of business. These lawsuits and
claims include actions involving product liability, intellectual
property, employment and environmental matters. Based on
information currently available, advice of counsel, established
reserves and other resources, we do not believe that any such
actions are likely to be, individually or in the aggregate,
material to our business, financial condition, results of
operations or liquidity. However, in the event of unexpected
further developments, it is possible that the ultimate
resolution of these matters, or other similar matters, if
unfavorable, may be materially adverse to our business,
financial condition, results of operations or liquidity.
There have been no significant changes in risk factors for the
quarter ended March 29, 2009. See the information set forth
in Part I, Item 1A of the Companys Annual Report
on
Form 10-K
for the fiscal year ended December 31, 2008.
33
|
|
Item 2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
Not applicable.
|
|
Item 3.
|
Defaults
Upon Senior Securities
|
Not applicable.
|
|
Item 4.
|
Submission
of Matters to a Vote of Security Holders
|
Not applicable.
|
|
Item 5.
|
Other
Information
|
Not applicable.
34
The following exhibits are filed as part of this report:
|
|
|
|
|
|
|
Exhibit No.
|
|
|
|
Description
|
|
|
31
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
31
|
.2
|
|
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a 14(a) under the Securities Exchange
Act of 1934.
|
|
32
|
.1
|
|
|
|
Certification of Chief Executive Officer pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
|
32
|
.2
|
|
|
|
Certification of Chief Financial Officer, Pursuant to
Rule 13a 14(b) under the Securities Exchange
Act of 1934.
|
35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
TELEFLEX INCORPORATED
Jeffrey P. Black
Chairman and
Chief Executive Officer
(Principal Executive Officer)
Kevin K. Gordon
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer)
|
|
|
|
By:
|
/s/ Charles
E. Williams
|
Charles E. Williams
Corporate Controller and
Chief Accounting Officer
(Principal Accounting Officer)
Dated: April 28, 2009
36